ATM / ATM serine / threonine kinase Antibody [ATM/9472]

• Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends.

• De Sarkar N, Dasgupta S, Chatterjee P, et al. Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight. 2021;6(23):e152789. Published 2021 Dec 8. doi:10.1172/jci.insight.152789
• De Sarkar N, Dasgupta S, Chatterjee P, et al. Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight. 2021;6(23):e152789. Published 2021 Dec 8. doi:10.1172/jci.insight.152789
• De Sarkar N, Dasgupta S, Chatterjee P, et al. Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight. 2021;6(23):e152789. Published 2021 Dec 8. doi:10.1172/jci.insight.152789

• https://pubmed.ncbi.nlm.nih.gov/35530152/
• https://pubmed.ncbi.nlm.nih.gov/34877933/
• https://pubmed.ncbi.nlm.nih.gov/29740495/
• https://pubmed.ncbi.nlm.nih.gov/32970977/
• https://pubmed.ncbi.nlm.nih.gov/30272350/
• https://pubmed.ncbi.nlm.nih.gov/11238376/
• https://pubmed.ncbi.nlm.nih.gov/31819689/

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

472

Q13315

11q22.3

370kDa

serine-protein kinase ATM, A-T mutated antibody; A-T mutated homolog antibody; AT mutated antibody; AT1 antibody; ATA antibody; Ataxia telangiectasia mutated antibody; Ataxia telangiectasia mutated gene antibody; Ataxia telangiectasia mutated homolog (human) antibody; Ataxia telangiectasia mutated homolog antibody; ATC antibody ATD antibody; ATDC antibody; ATE antibody ATM antibody; ATM serine/threonine kinase antibody; ATM_HUMAN antibody; DKFZp781A0353 antibody; MGC74674 antibody; OTTHUMP00000232981 antibody; Serine protein kinase ATM antibody; Serine-protein kinase ATM antibody; Serine/threonine-protein kinase ATM antibody; Tefu antibody TEL1 antibody; TEL1, telomere maintenance 1, homolog antibody; TELO1 antibody Telomere fusion protein antibody, AT1; ATA; ATC; ATD; ATE; ATDC; TEL1; TELO1